Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinodol
- Development stage
- Unknown
- Lead developer
- New Leaf Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Rhinodol is a prescription homeopathic nasal spray developed by New Leaf Pharmaceuticals, containing a combination of capsaicin and cannabidiol (CBD). It is indicated for the relief of headache pain and associated inflammation. Capsaicin acts as an agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) channel; its application to the nasal mucosa leads to the initial activation and subsequent desensitization of sensory neurons, providing analgesic effects. CBD is included for its potential anti-inflammatory and analgesic properties, interacting with various components of the endocannabinoid system and other ion channels. The product is registered with the FDA as a homeopathic drug for headache management.
- Brand names
- Rhinodol
- Other names
- capsaicin nasal spray with CBD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)
Beyond the preview
Go deeper on Rhinodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhinodol.